Alexander Drilon, MD presents updated results from a pooled analysis of TRK fusion-positive cancers treated with larotrectinib from the 2021 American Society of Clinical Oncology annual meeting.
Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center
Advertisement
Articles by Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center
Advertisement
Latest Updated Articles
Counseling Patients With NSCLC When KRAS is DetectedAugust 3rd 2020
Testing for KRAS Mutations in NSCLCAugust 3rd 2020
Current Management of Oncogene-Driven NSCLCAugust 3rd 2020
KRAS G12C Inhibition in Advanced NSCLC: MRTX849August 3rd 2020
Systemic Therapy for KRAS+ Advanced NSCLCAugust 3rd 2020
KRAS Mutations in Solid TumorsAugust 3rd 2020
Advertisement
Advertisement
Trending on OncLive
1
The OncFive: Top Oncology Articles for the Week of 7/12
2
CD33-Directed CAR T-Cell Therapies Elicit Complete Remissions in Relapsed/Refractory AML
3
Five Under 5: Top Oncology Videos for the Week of 7/12
4
Subcutaneous Pembrolizumab Faces Scrutiny Over Convenience and Cost for Patients With Cancer
5